C. Marco Timmers

Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985

Ronald C. Elgersma, Ruud G. E. Coumans, Tijl Huijbregts et al. · Molecular Pharmaceutics · 2015 · 214 citations · Full text

Molecular Biology, Duocarmycin 3B, Pharmaceutical Chemistry +16

The First Orally Active Low Molecular Weight Agonists for the LH Receptor: Thienopyr(im)idines with Therapeutic Potential for Ovulation Induction

Nicole C.R. van Straten, G. G. Schoonus-Gerritsma, R. G. van Someren et al. · ChemBioChem · 2002 · 104 citations

Lh Receptor, Therapeutic Potential, Gynecology +16

A signaling-selective, nanomolar potent allosteric low molecular weight agonist for the human luteinizing hormone receptor

Chris J. van Koppen, Guido J.R. Zaman, C. Marco Timmers et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 2008 · 97 citations

Molecular Pharmacology, Molecular Physiology, Signal Transduction +9

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression

Jonathan Black, Gulden Menderes, Stefania Bellone et al. · Molecular Cancer Therapeutics · 2016 · 91 citations · Full text

Identification of Substituted 6-Amino-4-phenyltetrahydroquinoline Derivatives:  Potent Antagonists for the Follicle-Stimulating Hormone Receptor

Nicole C.R. van Straten, Twan H. J. van Berkel, Dennis Demont et al. · Journal of Medicinal Chemistry · 2004 · 81 citations · Full text